EP 2182935 A1 20100512 - THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS
Title (en)
THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS
Title (de)
VERWENDUNG VON BENZAMID-DERIVATEN ZUR BEHANDLUNG VON LEIDEN DES ZENTRALEN NERVENSYSTEMS
Title (fr)
UTILISATION DE DÉRIVÉS DE BENZAMIDE POUR LE TRAITEMENT DE TROUBLES DU SNC
Publication
Application
Priority
- EP 2008059698 W 20080724
- EP 07113657 A 20070802
- EP 08786390 A 20080724
Abstract (en)
[origin: WO2009016088A1] The present invention relates to the use of a compound of formula (I), wherein R or a pharmaceutically acceptable acid addition salt thereof, for the manufacture of a medicament for the treatment of CNS disorders selected from depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress- related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
IPC 8 full level
A61K 31/166 (2006.01); A61K 31/167 (2006.01); A61P 3/00 (2006.01); A61P 9/00 (2006.01); A61P 9/12 (2006.01); A61P 25/00 (2006.01); C07D 213/00 (2006.01)
CPC (source: EP US)
A61K 31/166 (2013.01 - EP US); A61K 31/167 (2013.01 - EP US); A61P 3/00 (2017.12 - EP); A61P 3/04 (2017.12 - EP); A61P 3/06 (2017.12 - EP); A61P 3/10 (2017.12 - EP); A61P 9/00 (2017.12 - EP); A61P 9/12 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 25/04 (2017.12 - EP); A61P 25/06 (2017.12 - EP); A61P 25/08 (2017.12 - EP); A61P 25/16 (2017.12 - EP); A61P 25/18 (2017.12 - EP); A61P 25/20 (2017.12 - EP); A61P 25/22 (2017.12 - EP); A61P 25/24 (2017.12 - EP); A61P 25/28 (2017.12 - EP); A61P 25/30 (2017.12 - EP); C07C 233/65 (2013.01 - EP US); C07C 233/75 (2013.01 - EP US); C07C 235/56 (2013.01 - EP US); C07C 237/40 (2013.01 - EP US); C07C 255/57 (2013.01 - EP US); C07C 311/16 (2013.01 - EP US); C07C 311/21 (2013.01 - EP US); C07C 317/44 (2013.01 - EP US); C07D 205/06 (2013.01 - EP US); C07D 211/14 (2013.01 - EP US); C07D 213/82 (2013.01 - EP US); C07D 231/12 (2013.01 - EP US); C07D 263/32 (2013.01 - EP US); C07D 275/06 (2013.01 - EP US); C07D 295/155 (2013.01 - EP US); C07D 295/26 (2013.01 - EP US); C07D 401/04 (2013.01 - EP US)
Citation (search report)
See references of WO 2009016088A1
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
Designated extension state (EPC)
AL BA MK RS
DOCDB simple family (publication)
WO 2009016088 A1 20090205; AR 068049 A1 20091104; AU 2008281877 A1 20090205; AU 2008281877 A8 20100311; BR PI0815038 A2 20150317; CA 2695071 A1 20090205; CL 2008002246 A1 20090522; CN 101765425 A 20100630; EP 2182935 A1 20100512; JP 2010535172 A 20101118; KR 20100039429 A 20100415; PE 20090509 A1 20090429; TW 200911736 A 20090316; US 2009036420 A1 20090205
DOCDB simple family (application)
EP 2008059698 W 20080724; AR P080103286 A 20080730; AU 2008281877 A 20080724; BR PI0815038 A 20080724; CA 2695071 A 20080724; CL 2008002246 A 20080731; CN 200880101002 A 20080724; EP 08786390 A 20080724; JP 2010518626 A 20080724; KR 20107004579 A 20080724; PE 2008001288 A 20080731; TW 97129398 A 20080801; US 18056608 A 20080728